Janssens P A, Kleineke J, Caine A G
J Endocrinol. 1986 Apr;109(1):75-84. doi: 10.1677/joe.0.1090075.
Arginine vasotocin (AVT) caused a concentration-dependent increase of glycogen phosphorylase alpha activity, breakdown of glycogen and release of glucose, when added to pieces of axolotl liver in organ culture. The concentration causing half-maximal response (EC50) was about 1 nmol/l. These actions of AVT were unaffected by the adrenergic antagonists propranolol, yohimbine and prazosin, but were blocked by equimolar amounts of d(CH2)5Tyr(Me)AVT, a synthetic antagonist of vasopressin. Arginine vasotocin similarly caused glycogenolysis in isolated perfused axolotl liver where the EC50 was about 0.1 nmol/l. The glycogenolytic action of AVT (10 nmol/l) was sustained for at least 3 h in Ca2+-free perfusion and longer in organ culture. No increase in Ca2+ concentration in the effluent perfusion medium was apparent during AVT-induced glucose release. Omission of Ca2+ from the medium, together with addition of EGTA (2.5 mmol/l) to the organ culture, had only a slight inhibitory effect upon the rate of glycogenolysis brought about by AVT and did not inhibit the glycogenolytic action of catecholamines. Addition of the calcium ionophore A23187 (5 mumol/l) neither caused glucose release nor abolished the glycogenolytic action of AVT added subsequently. Nevertheless, A23187 caused increased loss of 45Ca from Ca2+-loaded liver pieces whereas AVT was without effect. There was a slight accumulation of cyclic AMP (cAMP), but not cGMP, in axolotl liver pieces cultured in the presence of 0.1 mumol AVT/l and this was accentuated in the presence of phosphodiesterase inhibitors. We conclude that, in contrast to the position in mammals, Ca2+ is not involved in the glycogenolytic actions of AVT or catecholamines in axolotl liver. Preliminary experiments suggest that the same is true in the carp and we suggest that the involvement of Ca2+ in regulation of hepatic glucose release may not have evolved until after the amphibians separated from the ancestors of the mammals.
将精氨酸血管加压素(AVT)添加到蝾螈肝脏组织块进行器官培养时,它会引起糖原磷酸化酶α活性浓度依赖性增加、糖原分解以及葡萄糖释放。引起半数最大反应的浓度(EC50)约为1 nmol/L。AVT的这些作用不受肾上腺素能拮抗剂普萘洛尔、育亨宾和哌唑嗪的影响,但会被等摩尔量的d(CH2)5Tyr(Me)AVT(一种血管加压素的合成拮抗剂)阻断。精氨酸血管加压素同样会在离体灌注的蝾螈肝脏中引起糖原分解,其EC50约为0.1 nmol/L。在无钙灌注中,AVT(10 nmol/L)的糖原分解作用至少持续3小时,在器官培养中持续时间更长。在AVT诱导葡萄糖释放过程中,流出的灌注培养基中钙浓度没有明显增加。培养基中去除钙并向器官培养物中添加乙二醇双四乙酸(EGTA,2.5 mmol/L),对AVT引起的糖原分解速率只有轻微抑制作用,且不抑制儿茶酚胺的糖原分解作用。添加钙离子载体A23187(5 μmol/L)既不引起葡萄糖释放,也不消除随后添加的AVT的糖原分解作用。然而,A23187会导致加载钙的肝脏组织块中45Ca损失增加,而AVT则无此作用。在含有0.1 μmol/L AVT的条件下培养的蝾螈肝脏组织块中,会有少量环磷酸腺苷(cAMP)积累,但环磷酸鸟苷(cGMP)没有积累,在磷酸二酯酶抑制剂存在的情况下这种积累会更明显。我们得出结论,与哺乳动物的情况不同,钙不参与AVT或儿茶酚胺在蝾螈肝脏中的糖原分解作用。初步实验表明鲤鱼也是如此,我们认为直到两栖动物与哺乳动物的祖先分离后,钙才参与肝脏葡萄糖释放的调节。